Vor Biopharma Inc. — Form 10-Q
Filed October 30, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 42/100
What the filing says
Vor Biopharma Inc. entered into an at-the-market (ATM) equity offering sales agreement dated October 30, 2026 with William Blair Company, L.L.C. and RBC Capital Markets, LLC. The company may issue and sell up to $150,000,000 of common stock through these agents at market prices, with a 3% selling commission. This is a shelf registration on Form S-3, permitting the company to raise capital opportunistically over time without fixed pricing or timing.
Why this rating
ATM offering of $150M is 197% of Vor's $76M market cap—a substantial potential dilution representing major liquidity event. However, significance is moderate-to-high (not 60+) because ATM programs are executed gradually, optionality is company's, and execution depends on market conditions. Real only if shares actually sell. Stock impact uncertain; positive for capital raise, negative if dilution heavy or stock price under pressure.
Extracted items
- 2.02 results / earnings
- 8.01 other event
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.